Nanoencapsulation
has
emerged
as
a
recent
improvement
in
the
delivery
of
drugs,
offering
and
improving
stability
bioavailability,
allowing
for
controlled
targeted
substances
to
specific
cells
or
tissues.
However,
traditional
nanoparticle
faces
challenges
such
short
circulation
time
immune
recognition.
To
address
these
issues,
cell
membrane-coated
nanoparticles
have
been
proposed
promising
alternative.
The
production
involves
three
key
stages:
lysis
membrane
fragmentation,
isolation,
coating.
Typically,
membranes
are
fragmented
using
hypotonic
combination
with
homogenization
sonication.
Subsequent
fragments
isolated
through
multiple
centrifugation
steps.
coating
can
be
achieved
extrusion,
sonication,
both
methods.
This
analysis
shows
absence
universally
applicable
method
coating,
stages
exhibit
notable
differences
their
procedures.
Here
we
review
ongoing
developments
approaches
that
position
this
technology
alternative
effective
drug
many
other
therapeutic
applications.
Science Translational Medicine,
Journal Year:
2024,
Volume and Issue:
16(735)
Published: Feb. 21, 2024
Osteoarthritis
(OA)
is
a
chronic
joint
disease
characterized
by
progressive
degeneration
of
articular
cartilage.
A
challenge
in
the
development
disease-modifying
drugs
effective
delivery
to
chondrocytes.
The
unique
structure
promotes
rapid
clearance
through
synovial
fluid,
and
dense
avascular
cartilage
extracellular
matrix
(ECM)
limits
drug
penetration.
Here,
we
show
that
poly(lactide-
co
-glycolic
acid)
nanoparticles
coated
chondrocyte
membranes
(CM-NPs)
were
preferentially
taken
up
rat
chondrocytes
ex
vivo
compared
with
uncoated
nanoparticles.
Internalization
CM-NPs
was
mediated
primarily
E-cadherin,
clathrin-mediated
endocytosis,
micropinocytosis.
These
adhered
ECM
knee
joints
penetrated
deeply
into
residence
time
more
than
34
days.
Simulated
fluid
studies
showed
loaded
Wnt
pathway
inhibitor,
adavivint
(CM-NPs-Ada),
delayed
catabolic
metabolism
human
explants
under
inflammatory
conditions.
In
surgical
model
OA,
drug-loaded
effectively
restored
gait,
attenuated
periarticular
bone
remodeling,
provided
chondroprotection
against
degeneration.
OA
progression
also
mitigated
CM-NPs-Ada
canine
anterior
cruciate
ligament
transection.
results
demonstrate
feasibility
using
membrane–coated
improve
pharmacokinetics
efficacy
anti-OA
drugs.
MedComm – Oncology,
Journal Year:
2024,
Volume and Issue:
3(1)
Published: March 1, 2024
Abstract
Rapid
growth
in
nanoparticles
(NPs)
as
delivery
systems
holds
vast
promise
to
promote
therapeutic
approaches
for
cancer
treatment.
Presently,
a
diverse
array
of
NPs
with
unique
properties
have
been
developed
overcome
different
challenges
and
achieve
sophisticated
routes
enhancement
series
therapies.
Inspiring
advances
achieved
the
field
therapy
using
NPs.
In
this
review,
we
aim
summarize
up‐to‐date
progression
addressing
various
challenges,
expect
elicit
novel
potential
opportunities
alternatively.
We
first
introduce
sorts
NP
technologies,
illustrate
their
mechanisms,
present
applications.
Then,
achievements
made
by
break
obstacles
delivering
cargoes
specific
sites
through
particular
are
highlighted,
including
long‐circulation,
tumor
targeting,
responsive
release,
subcellular
localization.
subsequently
retrospect
recent
research
treatments
from
single
therapy,
like
chemotherapy,
combination
chemoradiotherapy,
integrative
therapy.
Finally,
perspectives
impact
on
oncology
discussed.
believe
review
can
offer
deeper
understanding
Exploration,
Journal Year:
2024,
Volume and Issue:
4(6)
Published: March 21, 2024
Abstract
Cell
membrane‐coated
nanoparticles
(CMNPs)
have
recently
emerged
as
a
promising
platform
for
cancer
therapy.
By
encapsulating
therapeutic
agents
within
cell
membrane‐derived
coating,
these
combine
the
advantages
of
synthetic
and
natural
membranes.
This
review
provides
comprehensive
overview
recent
advancements
in
utilizing
CMNPs
effective
drug
delivery
vehicles
The
synthesis
fabrication
methods
are
comprehensively
discussed.
Various
techniques,
such
extrusion,
sonication,
self‐assembly,
employed
to
coat
with
membranes
derived
from
different
types.
membrane
coating
enables
biocompatibility,
reducing
risk
an
immune
response
enhancing
stability
bloodstream.
Moreover,
functionalization
strategies
CMNPs,
primarily
chemical
modification,
genetic
engineering,
external
stimuli,
highlighted.
presence
specific
surface
markers
on
coated
allows
targeted
cells
maximizes
efficacy.
Preclinical
studies
therapy
demonstrated
successful
various
agents,
chemotherapeutic
drugs,
nucleic
acids,
immunotherapeutic
using
CMNPs.
Furthermore,
article
explores
future
directions
challenges
this
technology
while
offering
insights
into
its
clinical
potential.
RSC Advances,
Journal Year:
2024,
Volume and Issue:
14(15), P. 10608 - 10637
Published: Jan. 1, 2024
This
review
summarized
the
function
of
cancer
cell
membranes
and
comprehensively
discussed
preparation
membrane-coated
nanoparticles
(CCM-NPs)
their
application
in
anti-tumor
therapy.
The
graphical
abstract
figure
was
drawn
by
Figdraw
(https://www.figdraw.com).
Bioactive Materials,
Journal Year:
2022,
Volume and Issue:
22, P. 239 - 253
Published: Oct. 7, 2022
Chemodynamic
therapy
(CDT),
a
noninvasive
strategy,
has
emerged
as
promising
alternative
to
conventional
chemotherapy
for
treating
tumors.
However,
its
therapeutic
effect
is
limited
by
the
amount
of
H2O2,
pH
value,
hypoxic
environment
tumors,
and
it
suboptimal
tumor-targeting
ability.
In
this
study,
tumor
cell
membrane-camouflaged
mesoporous
Fe3O4
nanoparticles
loaded
with
perfluoropentane
(PFP)
glucose
oxidase
(GOx)
are
used
microenvironment-adaptive
nanoplatform
([email
protected]2-G),
which
synergistically
enhances
antitumor
CDT.
Mesoporous
selected
inducers
photothermal
Fenton
reactions
nanocarriers.
GOx
depletes
within
cells
starving
cells,
while
producing
H2O2
subsequent
·OH
generation.
Moreover,
PFP,
can
carry
O2,
relieves
hypoxia
in
provides
O2
cascade
reaction.
Finally,
camouflaged
osteosarcoma
membranes,
endowing
homologous
targeting
immune
escape
abilities.
Both
vivo
vitro
evaluations
reveal
high
synergistic
efficacy
[email
protected]2-G,
desirable
tumor-inhibition
rate
(90.50%),
indicates
great
potential
platform
clinical
cancer.
Small,
Journal Year:
2023,
Volume and Issue:
19(43)
Published: June 28, 2023
Innate
immunity
triggered
by
the
cGAS/STING
pathway
has
potential
to
improve
cancer
immunotherapy.
Previously,
authors
reported
that
double-stranded
DNA
(dsDNA)
released
dying
tumor
cells
can
trigger
pathway.
However,
owing
efferocytosis,
are
engulfed
and
cleared
before
damaged
dsDNA
is
released;
hence,
immunologic
tolerance
immune
escape
occur.
Herein,
a
cancer-cell-membrane
biomimetic
nanocomposites
exhibit
tumor-immunotherapeutic
effects
synthesized
augmenting
suppressing
efferocytosis.
Once
internalized
cells,
combined
chemo/chemodynamic
therapy
would
be
triggered,
which
damages
their
nuclear
mitochondrial
DNA.
Furthermore,
releasing
Annexin
A5
protein
could
inhibit
efferocytosis
effect
promote
immunostimulatory
secondary
necrosis
preventing
phosphatidylserine
exposure,
resulting
in
burst
release
of
dsDNA.
These
fragments,
as
molecular
patterns
immunogenic
damage,
from
activate
pathway,
enhance
cross-presentation
inside
dendritic
M1-polarization
tumor-associated
macrophages.
In
vivo
experiments
suggest
proposed
nanocomposite
recruit
cytotoxic
T-cells
facilitate
long-term
immunological
memory.
Moreover,
when
with
immune-checkpoint
blockades,
it
augment
response.
Therefore,
this
novel
promising
strategy
for
generating
adaptive
antitumor
responses.
Pharmaceuticals,
Journal Year:
2023,
Volume and Issue:
16(1), P. 111 - 111
Published: Jan. 12, 2023
Multiple
myeloma
is
a
hematological
cancer
type.
For
its
treatment,
Bortezomib
has
been
widely
used.
However,
drug
resistance
to
this
effective
chemotherapeutic
developed
for
various
reasons.
2D
cell
cultures
and
animal
models
have
failed
understand
the
MM
disease
resistance.
It
therefore
essential
utilize
new
technologies
reveal
complete
molecular
profile
of
disease.
In
review,
we
in-depth
examined
possible
mechanisms
that
cause
specifically
addressed
Moreover,
also
included
use
nanoparticles,
3D
culture
methods,
microfluidics,
organ-on-chip
devices
in
multiple
myeloma.
We
discussed
whether
emerging
technology
offers
necessary
tools
prevent
Despite
ongoing
research
activities
on
MM,
related
studies
cannot
provide
summary
MM.
Nanoparticle
culturing
frequently
used
number
microfluidic
application
insufficient.
By
combining
siRNA/miRNA
with
devices,
genetic
could
be
revealed.
Microfluidic
chips
should
clinically
personal
therapy
point-of-care
applications.
At
least
microneedles,
it
ensured
patients
can
go
through
treatment
process
more
painlessly.
This
way,
switched
curable
type
list,
targeted
fewer
side
effects.